Single-agent anti-PD-(L)1 therapies have been authorized and are currently being used extensively for over 15 cancer indications, including solid tumors and hematologic malignancies, as a result of the quick advancement of clinical trials in these and other tumor types (94). This evidence concerns the gene CD274 and neoplasm.